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Anticancer immune responses can be enhanced by immune intervention that promotes complex biological mechanisms involving
severalcellularpopulations.Theclassicalimmunemonitoringforbiological-basedcancerclinicaltrialsisoftenbasedonsingle-cell
analysis. However, the overall eﬀect could be lost by such a reductionist approach explaining the lack of correlation among clinical
and immunological endpoints often reported. Microarray technology could give the possibility of studying in a multiparametric
setting the immune therapy eﬀects. The application of microarray is leading to an improved understanding of the immune
responses to tumor immunotherapy. In fact, analysis of cancer vaccine-induced host responses using microarrays is proposed
as valuable alternative to the standard cell-based methods. This paper shows successful examples of how high-throughput gene
expression proﬁling contributed to the understanding of anticancer immune responses during biological therapy, introducing as




Immune-based therapies that enhance the natural antitu-
mor immune response represent an attractive therapeutic
approach. However, the ongoing development of such ther-
apies, which includes vaccines, use of immune modulators,
DC therapy, and adoptive immunotherapy, has been labored
by the lack of a general method for the assessment of
quantity,functionalactivity,andoveralleﬀectoftheimmune
response. Immunologic monitoring of cancer immunother-
apytrialshasbeenhistoricallyfocusedoncell-basedassaysto
quantify tumor antigen-speciﬁc cellular immune responses
via phenotypic characterization or functional analysis asso-
ciated to an antigen-speciﬁc response [1–3]. A boost to
the immune monitoring derived from the development of
peptide-MHC Class I tetramers has become a key tool for
the antigen-speciﬁc cancer vaccine immune monitoring to
ex vivo identify, count, and isolate antigen-speciﬁc T cells
directly from blood patient samples [4, 5]. However, the
major disadvantages of such assay compared to other assays
suchasELISPOTorintracellularcytokineﬂowcytometryare
the low number of diﬀerent speciﬁcities that can be assessed
at the same time and the lack of functional characterization.
Thiscouldleadtoparadoxicalcoexistenceofatumor-speciﬁc
immune response and the progression of the disease [6, 7].
Even more, since immune therapy impacts multiple facets
of the immune response, those broad complex interactions
could easily be lost if the monitoring is focused and limited
tothe antigen-speciﬁcphenotypic immune response analysis
[8]. This was the case of tetramer-speciﬁc vaccine-induced
cells in a peptide-based cancer immunotherapy setting, since
the phenotypic characterization was showing a paradoxical
presence of tetramer-speciﬁc cells [2, 6], able to produce
interferon gamma [2] associated to clinical failure of the
therapy [8]. The interplay between cancer and immune
system, in the setting of cancer vaccine immune monitoring,2 Journal of Biomedicine and Biotechnology
must consider that both cancer and all the portion of the
immune system may aﬀect each other’s functionality by
direct contact or through the production of molecules with
immune modulatory properties. Such complexity could only
be recently appreciated in all its extent by high-throughput
tools capable of providing a global view of biological
processes [9]. Thanks to microarray analysis, we were able
to understand the paradoxical coexistence of tumor antigen-
speciﬁc cells and tumor in the same host by describing the
quiescent status of the antigen-speciﬁc T cells [6, 7]. In order
to dissect this complex interaction in a single-cell functional
focus, recently, the group of Heath proposed the use of
clinical microchip for the evaluation of single immune cell
functionality [10]. This innovative single-cell-based analysis
can lead to the resolution of the contribution of each single
cell to the overall eﬀect in response to therapy, suggesting
the possible use as a potential application to the ﬁeld of
immune monitoring for cancer vaccines as well [10]. This
study however can be considered complementary to the
informationthatisgeneratedthroughmicroarray.Infact,the
array technology leads to complementary information since
it is able to enlarge the view on the ﬁnal overall occurring
biological phenomena during the vaccination protocol as
resultant of the action of each single-cell activity.
2 .U s eo fM ic r oarra yt oR ev ealB io l ogic al
Response to Cancer Therapies
In human, one of the most characterized immune response
to a biological therapy through microarray technology is
the response to interferon alpha (IFN alpha), one of the
most used cytokine in clinics with the goal of activat-
ing the immune system in adjuvant setting. Zimmerer
et al. ﬁrst described the transcriptional response of T
cells, natural killer cells, and monocytes to IFN-alpha and
characterized the transcriptional proﬁles of PBMCs from
melanoma patients undergoing high dose of IFN-alpha
immunotherapy. In his study, he analyzed the proﬁle of in
vitro and in vivo immune cells stimulated with interferon
alpha showing a similar activation proﬁle in vivo and in
vitro. He proposed a signature associated to the eﬀect of
this therapy on the diﬀerent immune cell subpopulations,
suggesting the microarray analysis of in vitro stimulated
PBMCs as useful predictor of response tool [11]. Recently,
gene proﬁling analysis in similar setting was performed
by Berardelli’s group on PBMC isolated from melanoma
patients and healthy individuals 24 hours after each repeated
injection for a low-dose IFN-alpha, administered as vaccine
adjuvant in two separate clinical trials. This study was able
to characterize IFN-alpha mechanisms of action, ﬁnding a
core signature of these cytokines in the peripheral blood of
IFN-alpha-treated individuals, as well as on the existence
of blood genomic and proteomic markers of low-dose IFN-
alpha administered as a vaccine adjuvant. Those results
provide new insights into the identiﬁcation of a well-
deﬁned molecular signature as biomarker of low-dose IFN-
alpha administered as immune adjuvant [12]. A successful
application of immune monitoring through microarray
technology is for example the study of tumor response to
an attenuated recombinant vaccinia virus (GLV-1h68) that
selectively colonizes established human xenografts inducing
theircompleteregression. Inthis model, tumorrejectionwas
associated in vivo with activation of interferon-stimulated
genes and innate immune host-eﬀector functions [13]. In
this study, through the use of array technology, was clearly
demonstrated the synergy between the innate and adaptive
immune response required for successful tumor rejection.
In recent papers, the microarray technology was used in
order to monitor the immune response to cytokine-based
immunotherapy.
In a diﬀerent setting of experimental model, using a
mouse neuroblastoma cell line, Kohler demonstrated that
vaccination of tumor-free mice with a cell-based vaccine
leads to productive immunity and resistance to tumor
challenge,whilevaccinationoftumor-bearingmicedoesnot.
The T-cell immunity induced by this vaccine, as measured
by in vitro assays, is ampliﬁed by the depletion of Treg.
Our goal is to understand this barrier to the development
of protective cellular immunity. mRNA microarray analyses
of CD8(+) T cells from na¨ ıve or tumor-bearing mice
undergoing vaccination were carried out with or with-
out administering anti-CD25 antibody. Gene-expression
pathway analysis revealed the presence of CD8(+) T cells
expressing stem cell-associated genes early after induction of
productive antitumor immunity in tumor-free mice, prior
to any phenotypic changes, but not in tumor-bearing mice.
These data demonstrate that early after the induction of
productive immune response, cells within the CD8(+) T-cell
compartment adopt a stem cell-related genetic phenotype
that correlates with increased antitumor function [14, 15].
The microarray analysis has been able to clarify as well the
immunological functional status of cancer patient’s immune
system. Lee et al. were able to elucidate the nature of the
molecular bases of the immune dysfunction on melanoma
patient by comparing PBMCs from 12 healthy donors to
PBMCs from 12 melanoma patients. A high percentage
of signiﬁcantly altered genes in T cells and B cells from
melanoma patients belongs to interferon- (IFN-) stimulated
genes family, and the data was functionally validated since
the median percentage of lymphocytes that phosphorlate
STAT1 in response to IFN-alpha was signiﬁcantly reduced
in melanoma patients compared to healthy controls in
Phosﬂow analysis. Interestingly, this immune dysfunction
was reverted by administering high dose of interferon. In this
study, the application of microarray technology has led to
the deﬁnition of a new defects in interferon signaling as a





a set of genes that could become a model for monitoring
of antitumor immune response induced by antigen-speciﬁc
in vivo immune therapy. In this study, healthy donors
PBMCs were stimulated for 24 hours with the respective
antigen and analyzed for changes in gene expression. Of
all the genes diﬀerentially expressed, 85 were common toJournal of Biomedicine and Biotechnology 3
the four diﬀerent stimuli with CD40, showing the strongest
and most consistent upregulation upon antigen stimulation
of all genes analyzed. These results demonstrate the utility
of microarrays to investigate antigen-induced changes in
gene expression in PBMCs and provide support for the
use of microarrays in the immune monitoring of subjects
participating in therapeutic cancer vaccine trials [17].
3. New Software for Network
Analysis for the Translation from Dataset to
Biological Meaning
High-throughput technologies generate a big amount of
data leading to a parallel need of implement computa-
tional platforms that integrate pathway, protein-protein
interaction, genome, and literature mining data to result in
comprehensive networks for a list of genes or proteins. In
a recent and comprehensive review, Thomas and Bonchev
from the center for the study of biological complexity,
Virginia Commonwealth University, summarized the most
usedsoftwarefornetworkanalysisinlivingcells,thenodesin
whicharerepresentedasprotein-proteininteractionsorgene
regulatory networks [18]. They compared the three major
software packages for network analysis used CYTOSCAPE,
INGENUITY, and PATHWAY STUDIO, and in the same
paper, they compared in detail their characteristics as well
as their associated databases. For example, characteristic and
unique for the ingenuity pathway analysis is the database
for human genes/peptides created from manually evaluated
literature searches (Ingenuity ExpertAssist Findings). Not
included in the previous paper but of high interest is
a tool made available from the group of computational
Systems Biology Laboratory, Institute of Biomedicine and
Genome-Scale Biology Program at University of Helsinki.
Dr. Hautaniemi and Dr. Laakso have implemented a
computational platform (Moksiskaan) that is now able
to generate hypothetical pathways for a set of genes or
proteins as well as to estimate their activation statuses
using regulation information in pathway repositories. The
result of this type of analysis is a document that provides
description of the query genes and biological processes.
An important function is the generation of hypothetical
drug targets that can sensibly empower a translational type
of research in the oncologic ﬁeld. Moksiskaan networks
results can ultimately be analyzed as well in Cytoscape for
further personalized analysis. (Moksiskaan and user guide
are freely available under GNU General Public License at
http://csbi.ltdk.helsinki.ﬁ/moksiskaan/ [19].)
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